CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study

CureVac N.V. has announced the initiation of Part B of its Phase 1 clinical study for the cancer vaccine candidate CVGBM in patients with resected glioblastoma. This follows the completion of Part A, which involved dose-escalation and confirmed no dose-limiting toxicities among the 16 participants.

The open-label study will now include up to 20 patients in Part B to further evaluate the safety, tolerability, and immunogenicity of CVGBM. The vaccine employs a second-generation mRNA backbone to encode a fusion protein with eight epitopes shown to induce immune responses in glioblastoma.

The Data Safety Monitoring Board (DSMB) has recommended a 100 µg dose for Part B. Initial findings from Part A will be presented at the European Society for Medical Oncology Congress on September 13, 2024.